Rounding out in HPV

Roche has been looking for six years for a therapeutic vaccine to pair with its HPV diagnostics. It found what it wanted in Transgene S.A.'s TG4001 therapeutic vaccine.

Last week, Transgene (Euronext:Transgene, Strasbourg, France) granted Roche (SWX:ROG, Basel, Switzerland) exclusive, worldwide rights to develop and commercialize TG4001 to treat HPV-mediated diseases. ROG also received an exclusive,

Read the full 554 word article

How to gain access

Continue reading with a
two-week free trial.